Sumitomo Mitsui Trust Group Inc. Has $165.91 Million Position in Zoetis Inc. $ZTS

Sumitomo Mitsui Trust Group Inc. grew its position in Zoetis Inc. (NYSE:ZTS) by 7.5% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,133,883 shares of the company’s stock after purchasing an additional 79,140 shares during the period. Sumitomo Mitsui Trust Group Inc. owned about 0.26% of Zoetis worth $165,910,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in ZTS. Norges Bank acquired a new stake in Zoetis during the 2nd quarter worth $809,491,000. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in shares of Zoetis by 113.0% in the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,761,920 shares of the company’s stock worth $586,671,000 after acquiring an additional 1,995,491 shares in the last quarter. Corient Private Wealth LLC raised its position in shares of Zoetis by 85.9% during the second quarter. Corient Private Wealth LLC now owns 2,578,593 shares of the company’s stock worth $400,619,000 after purchasing an additional 1,191,840 shares during the period. Impax Asset Management Group plc lifted its holdings in shares of Zoetis by 362.6% during the 2nd quarter. Impax Asset Management Group plc now owns 1,176,996 shares of the company’s stock valued at $182,705,000 after purchasing an additional 922,589 shares in the last quarter. Finally, Swedbank AB grew its position in shares of Zoetis by 60.4% in the 3rd quarter. Swedbank AB now owns 2,436,888 shares of the company’s stock valued at $356,565,000 after purchasing an additional 917,598 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Trading Down 1.5%

Shares of NYSE:ZTS opened at $125.31 on Tuesday. The company’s 50-day moving average price is $122.90 and its two-hundred day moving average price is $140.26. Zoetis Inc. has a one year low of $115.25 and a one year high of $177.40. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.64 and a quick ratio of 2.28. The stock has a market capitalization of $55.22 billion, a PE ratio of 21.10, a price-to-earnings-growth ratio of 2.59 and a beta of 0.97.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.08. The company had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.42 billion. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.Zoetis’s revenue for the quarter was up .5% compared to the same quarter last year. During the same quarter last year, the company earned $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 3rd. Stockholders of record on Tuesday, January 20th will be paid a dividend of $0.53 per share. The ex-dividend date is Tuesday, January 20th. This represents a $2.12 annualized dividend and a dividend yield of 1.7%. This is a boost from Zoetis’s previous quarterly dividend of $0.50. Zoetis’s dividend payout ratio (DPR) is presently 33.67%.

Analyst Ratings Changes

Several analysts have commented on ZTS shares. Stifel Nicolaus dropped their target price on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a report on Tuesday, November 18th. BTIG Research restated a “buy” rating and set a $160.00 price objective on shares of Zoetis in a report on Wednesday, December 3rd. JPMorgan Chase & Co. reduced their target price on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. KeyCorp initiated coverage on Zoetis in a research note on Thursday, November 20th. They issued a “sector weight” rating on the stock. Finally, Barclays initiated coverage on Zoetis in a report on Monday, December 8th. They issued an “equal weight” rating and a $136.00 price target on the stock. Six investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $160.18.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.